Volume 4.43 | Oct 30

Mesenchymal Cell News 4.43 October 30, 2012
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs 
Cell Therapy News on Facebook  Mesenchymal Cell News on Twitter
Mesenchymal Stem Cells and Endothelial Progenitor Cells Decrease Renal Injury in Experimental Swine Renal Artery Stenosis through Different Mechanisms
Researchers tested the hypothesis that endothelial progenitor cells and mesenchymal stem cells protect the post-stenotic kidney by blunting different disease pathways. [Stem Cells] Abstract

Watch the Video: Obtain Functional MSCs Xeno-Free with MesenCult-XF
PUBLICATIONS (Ranked by impact factor of the journal)

The Potential Role of Epigenetics on Multipotent Cell Differentiation Capacity of Mesenchymal Stromal Cells
Investigators found that human umbilical cord perivascular cells exhibited increased telomerase activity and longer telomeres compared with bone marrow mesenchymal stromal cells. [Stem Cells] Abstract

Mesenchymal Stem Cells Promote Growth and Angiogenesis of Tumors in Mice
Using a xenograft model, human colorectal cancer cells, mesenchymal stem cells, and their cell mixture were introduced to a subcutaneous site of immunodeficient mice. The tumor growth rate and angiogenesis of each transplantation was then compared. [Oncogene] Abstract

Isolation of Osteoprogenitors from Human Jaw Periosteal Cells: A Comparison of Two Magnetic Separation Methods
To isolate osteoprogenitor cells from heterogeneous cell populations, scientists used the specific mesenchymal stem cell antigen-1 antibody and compared two magnetic separation methods. [PLoS One]
Full Article

Osteopontin Promotes Mesenchymal Stem Cell Migration and Lessens Cell Stiffness via Integrin β1, FAK, and ERK Pathways
Researchers found that osteopontin activated focal adhesion kinase (FAK) and extracellular signal-regulated kinase (ERK) signaling pathways by the ligation of integrin β1 in rat bone marrow-derived mesenchymal stem cells. [Cell Biochim Biophys] Abstract | Full Article

Pre-Treatment with IL-1β Enhances the Efficacy of MSC Transplantation in DSS-Induced Colitis
Investigators focused on the therapeutic efficacy of interleukin-1β (IL-1β)-primed mesenchymal stem cells (MSCs) in the dextran sulfate sodium (DSS)-induced colitis model, in addition to the underlining mechanisms. [Cell Mol Immunol] Abstract

Differential Expression of AURKA and AURKB Genes in Bone Marrow Stromal Mesenchymal Cells of Myelodisplastic Syndrome: Correlation with G-Banding Analysis and FISH
Scientists found that AURKA mRNA was expressed at significantly higher levels in mesenchymal stem cells even with normal/altered karyotype when compared with hematopoietic cells and healthy donors. [Exp Hematol] Abstract

An Orthopedic Tissue Adhesive for Targeted Delivery of Intraoperative Biologics
Researchers introduced the application of the biomaterial chondroitin sulfate succinimidyl succinate to deliver intraoperative biologics in a hydrogel adhesive. They demonstrated the biomaterial’s ability to bind various tissue types and its cellular biocompatibility with encapsulated human mesenchymal stem cells. [J Orthop Res] Abstract

In Vitro Assessment of Mesenchymal Stem Cells Immunosuppressive Potential in Multiple Sclerosis Patients
Using an in vitro model of lymphocytes and mesenchymal stem cells (MSC) cocultivation investigators revealed that the Index of MSC Suppression of myelin-induced memory T cells proliferation was stronger than that of PHA-stimulated proliferation and inversely correlated with patients’ EDSS score. [Immunol Lett] Abstract

Comparison of Tenocytes and Mesenchymal Stem Cells Seeded on Biodegradable Scaffolds in a Full-Size Tendon Defect Model
In order to investigate cell-based tendon regeneration, a tendon rupture was simulated by utilizing a critical full-size model in female rat achilles tendons. For bridging the defect, polyglycol acid and collagen type I scaffolds were used and fixed with a frame suture to ensure postoperatively a functional continuity. Scaffolds were seeded with mesenchymal stem cells or tenocytes derived from male animals, while control groups were left without cells. [J Mater Sci Mater Med] Abstract | Full Article

50,000 scientists receive our newsletters. Do your colleagues? Click to share this newsletter now.


Mechanisms of Mesenchymal Stromal Cell Immunomodulation
This review focuses on the mechanisms of mesenchymal stromal cell (MSC) immunomodulation discussing the multistep process of MSC localization at sites of inflammation, the cross talk between MSCs and the local microenvironment as well as the subsequent mechanisms of action used to resolve inflammation. [Immunol Cell Biol] Abstract

World Stem Cell Summit


NIH-CRM Awards Cellular Dynamics up to $7 Million to Produce Human Induced Pluripotent Stem Cells and Differentiated Tissue Cells
The National Institutes of Health Center for Regenerative Medicine (NIH-CRM) has awarded Cellular Dynamics International, Inc. a contract to provide human induced pluripotent stem cell lines and terminally differentiated tissue cells from normal or specified patient populations. The contract is worth up to $7.0 million for the three year life of the agreement. [Cellular Dynamics International, Inc.] Press Release

ViaCyte Receives $10.1 Million Strategic Partnership Award from CIRM to Continue Development of Diabetes Therapy
ViaCyte, Inc. announced that it has received a $10.1 million Strategic Partnership Award from the California Institute for Regenerative Medicine (CIRM). [ViaCyte Inc.] Press Release

Bioheart to Initiate ANGEL Trial in Mexico
Bioheart, Inc. has announced that it will initiate its ANGEL trial in Mexico at the Hospital Angeles with the Regenerative Medicine Institute. NorthStar Biotech LLC has agreed to fund the trial which will test the safety and efficacy of LipiCell™ (adipose derived stem cells) in congestive heart failure patients. [Marketwire]
Press Release


National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW International Conference of Personalized Medicine and Targeted Therapies in Cancer
January 31-February 2, 2013
Sharjah, United Arab Emirates

our events page to see a complete list of events in the mesenchymal cell community.


Quality Control Operations Coordinator (STEMCELL Technologies, Inc.)

Scientific Communications & Publishing Coordinator (STEMCELL Technologies, Inc.)

Product Manager – Hematopoietic (STEMCELL Technologies, Inc.)

Product Quality Scientist (STEMCELL Technologies, Inc.)

Scientist – Endothelial Cell Research (STEMCELL Technologies, Inc.)

Research Technologist – Cell Separation (STEMCELL Technologies, Inc.)

Research Associate – Quality Assurance (University of California)

Postdoctoral Position – Tumorigenicity of Mesenchymal Stem Cells Department of Molecular Cell Biology (Weizmann institute of Science)

Postdoctoral Position – Stem Cell and Cardiovascular Diseases (Zhejiang University School of Medicine)

Postdoctoral Position – Tumor Stem Cells (Cancer Institute of New Jersey)

Tenure-Track Assistant Professor – Vertebrate Stem Cell/Regenerative Biology (Harvard Stem Cell Institute)

Experienced Researcher (Hebrew University of Jerusalem)

Recruit Top Talent: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mesenchymal Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mesenchymal Cell News: Archives | Events | Contact Us